Fu Nianying, Tan Xiaotao, He Jie
Pulmonology Department, Guanghan Hospital of Traditional Chinese Medicine, DeYang, Sichuan, China.
Geriatric Department, Guanghan Hospital of Traditional Chinese Medicine, DeYang, Sichuan, China.
BMC Pulm Med. 2025 Feb 1;25(1):56. doi: 10.1186/s12890-025-03508-0.
This study seeks to elucidate variances in cystatin C levels between patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and controls while also assessing the impact of cystatin C on cardiovascular and cerebrovascular complications in patients with OSAHS. Furthermore, the benefits of surgery or continuous positive airway pressure (CPAP) treatment in reducing cystatin C levels in patients with OSAHS were explored.
A thorough search was undertaken across various medical databases, namely PubMed, CNKI, EMBASE, Web of Science, and WanFang, until October 1, 2024, to determine published articles pertinent to OSAHS. The present research conducted a comprehensive review of the literature concerning cystatin C levels in both patients with OSAHS and controls, variations in cystatin C levels pre-and post-surgery/CPAP treatment, the Pearson/Spearman correlation coefficients between cystatin C levels and sleep monitoring indices, and the hazard ratio (HR) associated with cystatin C levels concerning the onset of cardiovascular and cerebrovascular diseases among patients with OSAHS. Meta-analyses were executed utilizing standardized mean difference (SMD) and correlation coefficients (COR) as effect variables. A fixed-effect model was utilized in cases where heterogeneity was not significant (I < 50%). Otherwise, a random-effect model was employed. Statistical analysis was executed utilizing STATA 11.0, GraphPad Prism 8, and R 4.1.3.
Forty articles were included in the final analysis. The serum/plasma cystatin C levels in the OSAHS group were significantly increased relative to the controls (SMD = 0.65, 95%CI: 0.50-0.79, P < 0.001). Subgroup analysis considering mean body mass index (BMI), mean age, ethnicity, and study design type consistently showed significantly elevated serum/plasma cystatin C levels in the OSAHS category relative to the controls. CPAP treatment can significantly decrease serum/plasma cystatin C levels in patients with OSAHS. Moreover, the increase in cystatin C levels may serve as a risk factor for stroke and MACC in patients with OSAHS. Serum/plasma cystatin C levels exhibited a positive correlation with AHI scores and ODI.
Elevated cystatin C levels in patients with OSAHS may pose a risk for the onset of cardiovascular and cerebrovascular diseases. Furthermore, cystatin C levels could serve as a valuable clinical indicator for evaluating treatment effectiveness and severity of OSAHS.
Not applicable.
本研究旨在阐明阻塞性睡眠呼吸暂停低通气综合征（OSAHS）患者与对照组之间胱抑素C水平的差异，同时评估胱抑素C对OSAHS患者心血管和脑血管并发症的影响。此外，还探讨了手术或持续气道正压通气（CPAP）治疗对降低OSAHS患者胱抑素C水平的益处。
在2024年10月1日前，全面检索了多个医学数据库，即PubMed、CNKI、EMBASE、Web of Science和万方，以确定与OSAHS相关的已发表文章。本研究对有关OSAHS患者和对照组中胱抑素C水平、手术/CPAP治疗前后胱抑素C水平的变化、胱抑素C水平与睡眠监测指标之间的Pearson/Spearman相关系数，以及OSAHS患者中与胱抑素C水平相关的心血管和脑血管疾病发病的风险比（HR）的文献进行了全面综述。采用标准化均数差（SMD）和相关系数（COR）作为效应变量进行Meta分析。在异质性不显著（I<50%）的情况下，采用固定效应模型。否则，采用随机效应模型。使用STATA 11.0、GraphPad Prism 8和R 4.1.3进行统计分析。
最终分析纳入了40篇文章。OSAHS组的血清/血浆胱抑素C水平相对于对照组显著升高（SMD=0.65，95%CI：0.50-0.79，P<0.001）。考虑平均体重指数（BMI）、平均年龄、种族和研究设计类型的亚组分析一致显示，OSAHS组的血清/血浆胱抑素C水平相对于对照组显著升高。CPAP治疗可显著降低OSAHS患者的血清/血浆胱抑素C水平。此外，胱抑素C水平的升高可能是OSAHS患者发生中风和MACC的危险因素。血清/血浆胱抑素C水平与AHI评分和ODI呈正相关。
OSAHS患者胱抑素C水平升高可能是心血管和脑血管疾病发病的危险因素。此外，胱抑素C水平可作为评估OSAHS治疗效果和严重程度的有价值的临床指标。
不适用。
